Medicinal Chemistry News and Research

RSS

OSU-CG12 agent kills cancer cells through energy restriction: Study

Cancer cells grow so fast that they can outstrip their blood supply, leaving them short of oxygen. The cells then produce energy in a way that needs less oxygen but more sugar.

8 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

Potential new target for treating HCV infection

A team of scientists including University of Utah researchers has discovered that binding of a potent inhibitor of the hepatitis C virus to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus to replicate.

30 Mar 2010

New series of filters screen compounds for drug development

The identification of compounds that could be promising candidates for drug development has become easier following research by the Walter and Eliza Hall Institute's medicinal chemistry group.

25 Mar 2010

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

Cancer Research Technology has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the 'protein kinase C' superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 Mar 2010

SRI International researchers to disclose preliminary results of NTD detecting diagnostic at 239th ACS

SRI International, an independent nonprofit research and development organization, will present preliminary results of a diagnostic to detect neglected tropical diseases (NTDs) at the 239th National Meeting & Exhibition of the American Chemical Society (ACS) being held on March 21-25 in San Francisco.

22 Mar 2010

'Dipstick' 3-in-1 test for detection of Chagas' disease, leishmaniasis and African trypanosomiasis

A new simple, inexpensive three-in-one test to diagnose a terrible trio of parasitic diseases that wreak havoc in the developing world is passing preliminary tests, scientists reported here today. Described during the 239th National Meeting of the American Chemical Society the test is for Chagas' disease, leishmaniasis, and "sleeping sickness" or African trypanosomiasis.

22 Mar 2010

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

A collaborative project between Sanford-Burnham Medical Research Institute at Lake Nona and Analiza, Inc. has yielded aqueous solubility data for over 20,000 compounds in the NIH Molecular Library within the first 90 days of screening and characterization.

19 Mar 2010

Three scientists receive 2010 Discoverers Award for developing new class of HIV drug

Three scientists who led the 11-year quest to develop a groundbreaking HIV drug today received the 2010 Discoverers Award -- the highest honor given to scientists by the Pharmaceutical Research and Manufacturers of America. The honorees are Tony Wood, Ph.D., Elna van der Ryst, M.D., Ph.D. and Manos Perros, Ph.D.

19 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.

15 Mar 2010

Evotec, Active Biotech announce collaboration to identify small molecule modulators of priority biological target

Evotec AG today announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

11 Mar 2010

Papaya's anticancer effect against broad range of lab-grown tumors documented

The humble papaya is gaining credibility in Western medicine for anticancer powers that folk cultures have recognized for generations.

10 Mar 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today the finalization of the acquisition of the Discovery and Preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

8 Mar 2010

ExonHit Therapeutics includes proprietary lead compounds into collaboration with Allergan

ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.

23 Feb 2010

UCSF, Genentech partner to discover and develop drug candidates for neurodegenerative diseases

The University of California, San Francisco has signed a partnership agreement with Genentech, Inc., a wholly owned member of the Roche Group, to discover and develop drug candidates for neurodegenerative diseases.

19 Feb 2010

Eleven Biotherapeutics announces completion of $35M Series A funding

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company’s portfolio of engineered proteins through clinical proof of concept.

17 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

New class of compound could become effective antidepressant with minimal side effects

Chemists at Oregon State University have discovered and synthesized a new compound that in laboratory and animal tests appears to be similar to, but may have advantages over one of the most important antidepressant medications in the world.

5 Feb 2010

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).

5 Feb 2010

Medicinal Chemistry News and Research

OSU-CG12 agent kills cancer cells through energy restriction: Study

Cancer research at Georgia Tech: Report

Potential new target for treating HCV infection

New series of filters screen compounds for drug development

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

SRI International researchers to disclose preliminary results of NTD detecting diagnostic at 239th ACS

'Dipstick' 3-in-1 test for detection of Chagas' disease, leishmaniasis and African trypanosomiasis

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

Three scientists receive 2010 Discoverers Award for developing new class of HIV drug

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Evotec, Active Biotech announce collaboration to identify small molecule modulators of priority biological target

Papaya's anticancer effect against broad range of lab-grown tumors documented

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

ExonHit Therapeutics includes proprietary lead compounds into collaboration with Allergan

UCSF, Genentech partner to discover and develop drug candidates for neurodegenerative diseases

Eleven Biotherapeutics announces completion of $35M Series A funding

Medicinal chemistry paper related to the discovery of CUDC-101 published

New class of compound could become effective antidepressant with minimal side effects

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News